Phase 2 N=13 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
Parkinson's Disease
Primary: 31P-MRS Redox Ratio — 0.3856 Change in 31P-MRS Redox Ratio — p=0.1077
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
BK Virus Nephropathy · BK Virus Infection
Primary: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) — 17; 17; 16 Participants
Phase 2 N=73 ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Food Allergy
Primary: 600mg Desensitization in at Least One Qualifying Food — 8; 11; 4 Participants
Phase 2 N=100 A Study of FMT in Patients With AML Allo HSCT in Recipients
Acute Myeloid Leukemia · Allogeneic Hematopoietic Cell Transplantation
Primary: Efficacy of FMT in AML Patients and Allo-HCT Recipients - Number of Infections — 1.12; 1.50; 0.89; 1.09 Infections
Phase 2 N=36 Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Glioblastoma
Primary: Overall Survival at 12 Months (OS12) — 72.7 percentage of participants
Phase 2 N=197 Soy Isoflavones and Breast Cancer Risk Reduction
Breast Cancer
Primary: Fibroglandular Tissue in Total Breast (FGBT%) — 24.94; 25.34; 24.03; 25.82 percentage of total breast tissue — p=0.071
Phase 2 N=92 Use of Aromatherapy to Reduce Symptom Burden
Anxiety · Chemotherapy-induced Nausea and Vomiting
Primary: Chemotherapy-induced Nausea, Vomiting, and Retching (CINVR) Symptoms at Baseline, 25 Hours, and 48 Hours — 9.6; 8.5; 5.2; 4.9 score on a scale — p=0.462
Phase 2 N=64 A Study of TAK-071 in People With Parkinson Disease
Parkinson Disease · Healthy Participants
Primary: Main Cohort: Change From Baseline in Stride Time (Gait) Variability During a 2-minute Dual-Task Walking Test After 6-week Treatment With TAK-071 Compared With Placebo…
Phase 2 N=172 INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
Paroxysmal Atrial Fibrillation (PAF)
Primary: Percentage of Participants With Successful Conversion of Atrial Fibrillation to Sinus Rhythm — 10; 35; 33; 41 percentage of participants
Phase 2 N=37 Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Hypertension Pulmonary Secondary · Heart Failure, Right Sided · Heart Failure With Normal Ejection Fraction
Primary: Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP) With Bicycle Exercise — -1.9; -0.5 mmHg
Phase 2 N=42 BCAA Supplementation for Concussion
Brain Concussion
Primary: Reaction Time Difference Between Drug and Placebo Groups — 2.44; 2.49; 2.52; 2.48 log(milliseconds) — p=0.871
Phase 2 N=68 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Transitional Cell Carcinoma of Bladder · Urethra Cancer · Ureter Cancer
Primary: Maximum Tolerated Dose (MTD) and/or the Recommended Dose (RD) for Dose Expansion of ALT-801 in Combination With Cisplatin and Gemcitabine or ALT-801 in Combination With…
Phase 2 N=78 Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Progression-free Survival (PFS) Differences Between Ixabepilone Alone and Ixabepilone + Bevacizumab — 2.20; 5.46 months — p=<0.001
Phase 2 N=28 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Acute Myeloid Leukemia With Multilineage Dysplasia · Blasts 20-30 Percent of Bone Marrow Nucleated Cells · Blasts 20-30 Percent of Peripheral Blood White Cells
Primary: Number of Participants With a Response — 11 Participants
Phase 2 N=55 More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents
HIV Infections
Primary: Proportion of Participants Who Had Grade 3 or Higher Adverse Event (Cohort 1) — 0 proportion of participants